Guardant Health (GH) Research & Development (2017 - 2026)

Guardant Health has reported Research & Development for 10 years, with the latest figure at $190.0 million in Q2 2026.

• Quarterly Research & Development rose 58.84% year-over-year to $190.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $629.8 million (up 47.66% YoY) and the FY2025 annual result came in at $494.7 million, up 35.55% from the prior year.
• Research & Development improved to $190.0 million in Q2 2026 per GH's latest filing, from $169.1 million in the prior quarter.
• Over five years, Research & Development peaked at $190.0 million in Q2 2026 and troughed at $81.8 million in Q1 2022.
• A 5-year average of $109.1 million and a median of $98.9 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2026: Research & Development retreated 15.69% in 2023, then jumped 62.13% in 2026.
• Over 5 years, Research & Development stood at $106.6 million in 2022, then dropped by 15.69% to $89.9 million in 2023, then rose by 16.59% to $104.8 million in 2024, then jumped by 36.86% to $143.4 million in 2025, then surged by 32.48% to $190.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $190.0 million, $169.1 million, and $143.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.